COVID-19 outbreak in a psychiatric hospital: what makes it worse?

Marouan Zoghbi¹,², Chadia Haddad¹,³,⁴, Wael Khansa⁵, Elie Karam¹, Angela Chamoun¹ and Dory Hachem*¹

Abstract

Background: Psychiatric patients could be at risk of worse outcomes from COVID-19 than the general population. The primary objective of the present study was to describe the symptoms and clinical characteristics of COVID-19 patients living in long-term hospital for mental illness in Lebanon. The secondary objective was to evaluate the factors related to COVID-19 disease severity among these patients.

Methods: A retrospective observational study was conducted from September 2020 to January 2021 at the Psychiatric Hospital of the Cross. The total number of COVID-19 patients in the infected floors is 410 out of 548. The outcome variable was the severity of COVID-19 illness classified into five categories: asymptomatic, mild, moderate, severe and critically ill.

Results: The rate of infection in the affected floors was 74.81%. Almost half of the patients were asymptomatic (49.3%), 43.4% had hyperthermia and only 28.0% had tachycardia and 25.1% developed hypoxia. The multivariate regression analysis showed that higher temperature (ORa=6.52), lower saturation (ORa=0.88), higher BMI (ORa=1.12), higher CRP (ORa=1.01), being a female (ORa=4.59), having diabetes (ORa=8.11) or COPD (ORa=10.03) were significantly associated with the increase of the COVID-19 severity.

Conclusions: The current study showed that a high rate of infection from COVID-19 was detected in a psychiatric hospital with the majority having asymptomatic to mild symptoms. Female psychiatric patients, desaturation, increase inflammation and comorbidities such as diabetes and COPD were associated with the severity of COVID-19 among psychiatric patients. Future studies are needed to better understand the causal relation of the factors with severity and long term effects or sequelae of the disease.

Keywords: COVID-19, Mental disorders, Psychiatric hospitals, Outbreak, Symptoms, COVID-19 illness severity

Introduction

Psychiatric patients is one of the most vulnerable populations affected by the COVID-19 pandemic [1–3]. This vulnerability is related to higher transmission and poor outcomes. Most individuals with severe mental illness live in institutional environment, such as hospital, units for treatment, hostels, nursing home, and prisons [4, 5]. These populations are at increased risk of infectious disease outbreaks as they reside in close overcrowded environment and interact closely and frequently with nursing staff, and use shared spaces, such as bathrooms and dining room [6]. In addition, psychiatric patients has high rates of physical health comorbidities, such as obesity, hypertension, and metabolic syndrome, as well as high rates of neurocognitive impairment [7–10]. They are more likely than the general population to become infected with COVID-19, and they are more than twice as likely to develop a severe outcome of COVID-19 infection [11, 12].
Risk factors among psychiatric patients for severe infection are highly prevalent, such as increased rates of obesity, cardiovascular disease and chronic obstructive pulmonary disease [8, 13–15]. In addition, gender is a risk factor for increased severity and death in individuals with COVID-19. Previous coronavirus outbreaks, such as SARS-CoV-2 (2002) and the Middle Eastern respiratory syndrome coronavirus (MERS, 2012), revealed gender inequalities in their expression, with males typically being more seriously afflicted than women [16–18]. In COVID-19 infection some studies found a greater incidence of infection in males [19–22], whereas others found no difference in COVID-19 infection rates between men and women [23–26]. This might be due to a higher risk of exposure in males, as well as, access to healthcare and diagnostic options [26]. In addition, the lifestyle factors, including smoking and physical inactivity could have an effect on the disease prognosis [13]. Also, treatment with antipsychotics could be associated with COVID-19 infection severity [13].

In Lebanon, the Psychiatric hospital of the Cross (HPC), the largest inpatient psychiatric hospital, had responded rapidly to the COVID-19 outbreak in the country by adopting confinement measures such as temporally stopping new inpatient admissions and prohibiting visits from family members to existing inmates. The outpatients’ department was also closed and the medical students were turned to online sessions. Despite these measures, two outbreaks of COVID-19 among patients were observed in the HPC in September 2020 and January 2021. In response to this outbreak, the infected wards were fully isolated. All patients in the ward as well the staff were tested for COVID-19 and those who turned positive were immediately shifted to isolation. Adequate staff training was launched and personal protection equipment was properly supplied. Another unit was created inside the hospital premises to take care of patients needing oxygen supplementation and any form of non-invasive ventilation. Patients requiring invasive ventilation were transferred to COVID ICU floors in other hospitals in a medically assisted transport ambulance.

Early diagnosis and identification of COVID-19 infection in psychiatric patients and prompt response in terms of infection control measures improve treatment outcomes [27]. As far as we know, data scarcity had reported an outbreak in psychiatric settings. In China, an outbreak occurred in a hospital, where 50 inpatients and 30 health professionals were tested positive in February 2020 [4]. In USA, 63 psychiatry hospitals had outbreaks of COVID-19 and as an example one patient became symptomatic and tested positive for COVID-19; almost 80% of the other patients who were living in the same building (n = 65) were tested positive within 2 weeks [28, 29]. The scarcity of information is known about the prognostic factors in COVID-19 management in patients with severe mental diseases and living in chronic care facilities. The primary objective of the present study was to describe the symptoms and clinical characteristics of COVID-19 patients living in long-term hospital for mental illness in Lebanon. The secondary objective was to evaluate the factors related to COVID-19 disease severity among these patients.

Methods
Study design and subjects
A retrospective cross-sectional study was conducted during two local outbreaks of COVID-19 between September 2020 and January 2021 at the Psychiatric Hospital of the Cross. The inclusion criteria were patients with chronic mental illness treated as internal patients at the aforementioned hospital and with a confirmed diagnosis of COVID-19. During the first outbreak, 94 male inpatients were identified as having COVID-19 and in the second outbreak in January 2021, 316 patients were identified as having COVID-19. The total sample of detected COVID-19 patients were 410.

Procedures and assessments
Data was extracted from medical files and nursing notes of included patients. Nursing note in the hospital are written by the nursing staff and every info is checked by a second nurse to ensure data validity and avoid errors. Non-additional data was required for the study outside the routine data collected. Daily notes were reviewed when necessary.

The data collected were clinical data that include: socio-demographic characteristics (age, gender and Body mass index (BMI)), the daily COVID-19 symptoms (cough, throat, diarrhea, conjunctivitis, headache, loss of smell, difficulty breathing, chest pain), vital signs (body temperature, pulse rate, respiration rate, SpO2 and blood pressure), laboratory tests (counts of white blood cells and red blood cells, neutrophils, and lymphocytes, liver enzymes and C-reactive protein (CRP)), comorbidities (diabetes, coronary heart disease, hypertension, being tested for tuberculosis (purified protein derivative (PPD) test) and chronic obstructive pulmonary disease (COPD)). In addition, the treatment (Psychiatric and medical treatment) was collected, such as antipsychotic medications, mood stabilizing medications, benzodiazepines, anti-epileptic, antidepressants, anti-hypertensive, anti-diabetic, anti-coagulant and statin medications. The BMI was calculated as body weight in kilograms divided by the square of the height in meters (kg/m2).

The severity of COVID-19 illness was considered as the outcome variable and defined according to the WHO
guidelines [3] and the COVID-19 treatment guidelines issued by the National Institutes of health (NIH) [30]. Patients were classified into five categories according to the following criteria: Asymptomatic: Individuals who are tested positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test or an antigen test) but have no symptoms. Mild illness: Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but do not have shortness of breath or dyspnea or hypoxia. Moderate illness: Individuals who show evidence of lower respiratory disease during clinical assessment and who have saturation of oxygen (SpO2) ≥ 94%. Severe illness: Individuals who have oxygen saturation < 94%, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) < 300 mm Hg or a respiratory frequency > 30 breaths/min. Critical illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

**Statistical analysis**

Data were analyzed on SPSS software version 25. A descriptive analysis was performed using absolute frequencies and percentages for categorical variables, means and standard deviations (SD) for quantitative measures. For testing group differences with the outcome variable, Chi-square test or Fisher’s exact test was used for categorical variables and ANOVA F tests were used for the continuous variable.

Ordinal logistic regression was conducted taking the COVID-19 illness categories as the dependent variables. All the variables that showed a p value < 0.2 in the bivariate analysis were included in the model to eliminate potential confounding factors. A P value less than 0.05 was considered significant.

**Results**

**Sociodemographic and COVID-19 symptoms characteristics**

The mean age of included patients was 52.42 ± 16.63 years, with 66.3% males. Half of the patients were smokers 51.2% and the mean BMI was 23.73 ± 3.30. The rate of infection in the affected floors was 74.81%. Almost half of the patients were asymptomatic (49.3%), 43.4% had hyperthermia (43.4%), only 28.0% had tachycardia and 25.1% had low saturation. The reported mortality rate from COVID-19 diagnosis up to 27 days of follow-up was 4.6% (Table 1). Among 149 psychiatric women residing in the hospital, 140 (93.9%) have been infected with COVID-19; however, 60.3% of psychiatric men got the virus.

| Table 1 | Description of COVID-19 symptoms among psychiatric patients (n = 410) |
|---------|------------------------------------------------------------------------|
| Frequency |
| **COVID-19 illness classification** |  |
| Asymptomatic | 202 (49.3%) |
| Mild | 145 (35.4%) |
| Moderate | 5 (1.2%) |
| Severe | 37 (9.0%) |
| Critical | 21 (5.1%) |
| **COVID-19 symptoms** |  |
| Cough | 36 (8.8%) |
| Throat pain | 5 (1.2%) |
| Diarrhea | 12 (2.9%) |
| Conjunctivitis | 8 (2.0%) |
| Headache | 23 (5.6%) |
| Loss of smell | 5 (1.2%) |
| Difficulty breathing | 17 (4.1%) |
| Chest pain | 8 (2.0%) |
| **Temperature** |  |
| Normal temperature | 232 (56.6%) |
| Hyperthermia | 178 (43.4%) |
| **Pulse** |  |
| Normal | 295 (72.0%) |
| Tachycardia | 115 (28.0%) |
| **Saturation** |  |
| Normal | 307 (74.9%) |
| Abnormal | 103 (25.1%) |
| **Patients requiring oxygen supplementation in the psychiatric institution** | 30 (7.3%) |
| **Patients requiring mechanical ventilation** | 4 (1.0%) |
| **Patients transferred to specialized hospital** | 18 (4.4%) |
| **Death** | 19 (4.6%) |

**Description of comorbidities**

The prevalence of diabetes among our sample was 7.8%, hypertension (12.0%), coronary heart disease (2.7%) and COPD comorbid association rate was 3.9%. Only 23.4% have a positive reaction to the PPD test (Table 2).

**Description of the medications**

The majority of the patients were taking typical antipsychotics (73.4%) and only 32.4% were taking the atypical one. More than half of the patients were taking anti-cholinergic (64.3%), 45.6% were taking anti-epileptic and 36.3% were taking benzodiazepines. Almost half of the patients were taking more than one neuroleptic (49.5%). Other treatments taken by the patients are detailed in Table 3.
Bivariate analysis
The bivariate analysis taking the COVID-19 illness categories as the dependent variable is presented in Table 4. The results showed that a significantly higher proportion of female patients have severe to critical cases as compared to male patients. Those having diabetes and COPD had more severe critical cases compared to those who did not have these diseases. A higher proportion of patients who take anti-epileptic medication and antipsychotic treatment had less critical cases as compared to those who do not take these medications. Those who take Benzodiazepines had more severe cases as compared to those who do not take this medication. In addition, a higher mean age, temperature, pulse and higher CRP level were significantly associated with severe to critical cases of COVID-19. However, a lower mean saturation and lower mean number of typical antipsychotic were significantly associated with critical cases of COVID-19.

Multivariable analysis
The ordinal regression analysis, taking the severity of the COVID-19 disease as the dependent variable, showed that higher temperature (ORa = 6.52), lower saturation (ORa = 0.88), higher BMI (ORa = 1.12), higher CRP (ORa = 1.01), being a female (ORa = 4.59), having diabetes (ORa = 8.11) and COPD (ORa = 10.03) were significantly associated with the increase on the COVID-19 severity. The use of treatment (anti-epileptic, antipsychotic, and mood stabilizer) were not associated with the severity of the COVID-19 (p > 0.05) (Table 5). The two most contributor factors to the severity of the COVID-19 were COPD and diabetes followed by gender and temperature (Fig. 1).
The main result of the study is a female, having diabetes and COPD, higher BMI, higher temperature and desaturation is related to a higher COVID-19 severity. However, we could not find any statistically significant association after adjustment between the medication used and the severity of COVID-19. COVID-19 pandemic has hit multiple parts of the HPC hospital in many ways as it is more considered as residential institution, where an overcrowded number of patients with different psychiatric disease live together. In this hospital, 74.81% of the patients from the infected floors were infected by

| Table 4 | Bivariate analysis taking the COVID-19 illness categories as the dependent variable |
|---------|-----------------------------------------------------------------------------------|
|         | Asymptomatic | Mild | Moderate | Severe | Critical | \( p \) value |
| Gender  | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) | Frequency (%) |
| Male    | 126 (46.3%) | 113 (41.5%) | 5 (1.8%) | 15 (5.5%) | 13 (4.8%) | <0.001 |
| Female  | 76 (55.1%) | 32 (23.2%) | 0 (0%) | 22 (15.9%) | 8 (5.8%) |
| Diabetes |          |          |          |          |          | 0.037 |
| Yes     | 10 (31.3%) | 13 (40.6%) | 1 (3.1%) | 7 (21.9%) | 1 (3.1%) |
| No      | 192 (50.8%) | 132 (34.9%) | 4 (1.1%) | 30 (7.9%) | 20 (5.3%) |
| Hypertension |          |          |          |          |          | 0.057 |
| Yes     | 22 (44.9%) | 18 (36.7%) | 0 (0%) | 9 (18.4%) | 0 (0%) |
| No      | 180 (49.9%) | 127 (35.2%) | 3 (1.4%) | 28 (7.8%) | 21 (5.8%) |
| Coronary heart disease |          |          |          |          |          | 0.057 |
| Yes     | 8 (72.7%) | 0 (0.0%) | 0 (0%) | 1 (9.1%) | 2 (18.2%) |
| No      | 194 (48.6%) | 145 (36.6%) | 5 (1.3%) | 36 (9.0%) | 19 (4.8%) |
| Chronic obstructive pulmonary disease |          |          |          |          |          | 0.001 |
| Yes     | 1 (6.3%) | 8 (50.0%) | 1 (6.3%) | 3 (18.8%) | 3 (18.8%) |
| No      | 201 (51.0%) | 137 (34.8%) | 4 (1.0%) | 34 (8.6%) | 18 (4.6%) |
| Smoking |          |          |          |          |          | 0.002 |
| Yes     | 98 (46.7%) | 88 (41.9%) | 2 (1.0%) | 19 (9.0%) | 3 (1.4%) |
| No      | 104 (52.0%) | 57 (28.5%) | 3 (1.5%) | 18 (9.0%) | 18 (9.0%) |
| Atypical ATP |          |          |          |          |          | 0.130 |
| Yes     | 72 (54.1%) | 44 (33.1%) | 1 (0.8%) | 14 (10.5%) | 2 (1.5%) |
| No      | 130 (46.9%) | 101 (36.5%) | 4 (1.4%) | 23 (8.3%) | 19 (6.9%) |
| Typical ATP |          |          |          |          |          | <0.001 |
| Yes     | 154 (51.2%) | 115 (38.2%) | 5 (1.7%) | 25 (8.3%) | 2 (0.7%) |
| No      | 48 (44.0%) | 30 (27.5%) | 0 (0%) | 12 (11.0%) | 19 (17.4%) |
| Anti-epileptic |          |          |          |          |          | 0.031 |
| Yes     | 85 (45.5%) | 76 (40.6%) | 3 (1.6%) | 19 (10.2%) | 4 (2.1%) |
| No      | 117 (52.5%) | 69 (30.9%) | 2 (0.9%) | 18 (8.1%) | 17 (7.6%) |
| Benzodiazepine |          |          |          |          |          | 0.003 |
| Yes     | 76 (51.0%) | 57 (38.3%) | 0 (0%) | 16 (10.7%) | 0 (0%) |
| No      | 126 (48.3%) | 88 (33.7%) | 5 (1.9%) | 21 (8.0%) | 21 (8.0%) |

| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD |
|-----------|-----------|-----------|-----------|-----------|
| Age       | 48.78 ± 17.10 | 47.92 ± 17.72 | 64.66 ± 2.08 | 63.50 ± 10.60 | 60.63 ± 11.91 | 0.002 |
| BMI       | 23.14 ± 3.09 | 24.08 ± 3.25 | 26.03 ± 5.15 | 24.13 ± 3.56 | 26.72 ± 2.43 | 0.097 |
| Temperature | 36.89 ± 0.34 | 38.36 ± 0.79 | 38.46 ± 0.64 | 39.48 ± 1.03 | 39.70 ± 0.88 | <0.001 |
| Pulse     | 91.80 ± 12.20 | 96.24 ± 11.83 | 103.66 ± 13.86 | 90.77 ± 10.64 | 102.85 ± 19.29 | 0.001 |
| Saturation | 97.11 ± 2.46 | 95.55 ± 3.40 | 89.00 ± 3.00 | 89.45 ± 6.87 | 88.25 ± 3.77 | <0.001 |
| Number of typical antipsychotic | 1.16 ± 0.87 | 1.30 ± 0.95 | 1.40 ± 0.54 | 1.10 ± 0.96 | 0.95 ± 0.30 | <0.001 |
| Number of atypical antipsychotic | 0.39 ± 0.55 | 0.31 ± 0.49 | 0.20 ± 0.44 | 0.45 ± 0.64 | 0.09 ± 0.30 | 0.078 |
| CRP       | 13.80 ± 22.82 | 33.05 ± 40.27 | 86.20 ± 98.89 | 80.36 ± 58.31 | 75.89 ± 61.33 | <0.001 |

Values marked in bold are significant

**Discussion**

The main result of the study is a female, having diabetes and COPD, higher BMI, higher temperature and desaturation is related to a higher COVID-19 severity. However, we could not find any statistically significant association after adjustment between the medication used and the severity of COVID-19. COVID-19 pandemic has hit multiple parts of the HPC hospital in many ways as it is more considered as residential institution, where an overcrowded number of patients with different psychiatric disease live together. In this hospital, 74.81% of the patients from the infected floors were infected by...
COVID-19. These numbers come in alignment with the rates in some psychiatric wards like the building 0 in a US state psychiatric hospital setting, where the rate of infection was around 78% (51 out of 65 patients) [29]. Given the big number of patients in the hospital, the physical structure of psychiatric units, the difficulties faced in isolating patients with behavioral problems and the limited number of nurses needed to monitor patients have raised the number of COVID-19 infection. In addition, several patients were unable to abide by social distancing rules because of their cognitive and psychiatric conditions. Therefore, the rapid infection in the psychiatric ward was high whenever one patient or a health care worker was tested positive.

When comparing the rates of symptomatic infection among psychiatric inpatients with the general population of Lebanon, psychiatric patient had a lower risk of developing a severe/critical infection (14% vs 20% in the general population) [31]. This could be explained by the closer monitoring of patients and early interventions done. Another explanation could be related to a protective effect of some neuroleptics as suggested by Gordon et al. [32], the anti-viral properties of haloperidol and chlorpromazine, and the typical antipsychotic widely

| Beta | p value | ORa | 95% Confidence interval |
|------|---------|-----|------------------------|
| Temperature | 1.874 | <0.001 | 6.520 | 3.704 | 12.672 |
| Saturation | -0.124 | 0.016 | 0.883 | 0.794 | 0.972 |
| BMI | 0.118 | 0.016 | 1.125 | 1.025 | 1.244 |
| Age | 0.015 | 0.360 | 1.016 | 0.982 | 1.051 |
| Gender (Female vs Male*) | 1.524 | 0.022 | 4.591 | 1.281 | 17.834 |
| Diabetes (yes vs no*) | 2.093 | 0.004 | 8.110 | 1.980 | 36.095 |
| COPD (yes vs no*) | 2.306 | 0.011 | 10.039 | 1.805 | 64.611 |
| CRP | 0.011 | 0.018 | 1.012 | 1.002 | 1.022 |
| Anti-epileptic treatment (Yes vs No*) | 0.523 | 0.232 | 1.689 | 0.718 | 4.044 |
| Aspirin medication treatment (Yes vs No*) | 0.074 | 0.933 | 1.077 | 0.189 | 6.076 |
| Typical antipsychotics (Yes vs No*) | 0.040 | 0.933 | 1.041 | 0.405 | 2.694 |
| Mood stabilizer (Yes vs No*) | 0.441 | 0.522 | 1.556 | 0.400 | 6.130 |

*Reference group
Values marked in bold are significant.

**Table 5** Ordinal regression analysis taking the COVID-19 illness categories as the dependent variable

**Fig. 1** Factors associated with the COVID-19 illness among psychiatric patients
used in the hospital could be a potential explanation for this decreased risk. The low rate of severe cases raises the possible positive effect of those drugs and their anti-viral properties.

On another level, ivermectin was used by the majority of patients (71.2%) as part of treatment at the discretion of the treating physician and this may have reduced the progressing numbers to severe disease.

In our study, 49.3% of patients were tested positive while staying asymptomatic. These numbers match to a certain degree with the previous study done in building 0, where 88% of asymptomatic patients were tested positive for COVID-19 and the rate of asymptomatic infected patients was around 30% of all positive cases in building 0 [29]. It is also notable that our study shows 33% of positive patients having only mild symptoms in line with the numbers found in building 0, where around 25% of positive patients had only mild symptoms [29]. These numbers show that the clear predominance of asymptomatic and mildly symptomatic patients between positive cases.

The regression analysis of our study shows that higher temperature and desaturation is related to a higher COVID-19 severity. This comes in line with the meta-analysis done by Li et al. [33], where both fever and dyspnea were associated with an increased severity of the COVID-19 infection [33]. A retrospective study done in China among eighty COVID-19 patients have demonstrated that the COVID-19 severity was associated with fever and PO2 < 80 mm Hg on admission [34]. Our results suggest that dyspnea and fever are risk factors of severe illness, therefore, requiring a closer monitoring of these patients for earlier intervention.

In our study, having diabetes and COPD were associated with a higher risk of severe infection, in line with the meta-analysis done by Jia Li et al., patients having any comorbidity, including COPD and diabetes had a higher rate of severe illness. This suggests that any comorbidity should be assessed in positive patients for closer monitoring of their illness.

It is also important to note that our study found that a higher CRP was associated with an increased risk of severe infection in line with Jia Li et al. meta-analysis in which CRP level was also associated with an increased risk of severe illness and ICU admission [33]. Therefore, a close monitoring of the CRP levels could be helpful in predicting severe illness especially when it comes to mass testing in hospitals with a big number of patients. By that minimizing the blood work up for a rapid evaluation of the severity of the COVID-19 infections.

In our study a higher BMI was also associated with a higher COVID-19 severity like with a systemic review and a meta-analysis of 22 studies done by Yanan Chu et al., where obesity and increased BMI were associated with severe illness and worst outcomes [35]. Given that psychiatric patients are at higher risk of obesity given the well-known side effects of SGA, this suggests that long term monitoring of weight is important on the long run, especially during a pandemic like COVID-19.

The results of this study showed that females have higher risk to develop severe COVID-19 illness than men. The number of studies that particularly assess the sex differences in COVID-19-related symptoms was limited, and the results were conflicting. The study done by Takahashi et al. have found that men were at a higher risk of developing a severe illness [36]. In addition, prior research had suggested that male patients had a greater severity and mortality rate [37–39]. A study done by Wang et al. found that women with a recent diagnosis of a mental disorder had higher odds of COVID-19 infection than men after adjusting for age, ethnicity and medical comorbidities [11]. The results could be explained by the higher infection rate among women as reported by an internal hospital report that showed that the incidence of the virus among women were 93.9% and among men was 60.3% that could explain partially the results. In addition, other risk variables might be related to the severity of the disease among women, such as age and the number of medical comorbidities. Moreover, it might be the presence of biological difference in receptors expression (angiotensin-converting enzyme-2 and transmembrane protease serine 2) between males and females as well as immunological differences [40, 41]. Females’ have lower production of pro-inflammatory interleukin-6 (IL-6) following viral infection that could explain the development of COVID-19 symptoms [40, 41]. More studies are needed to better understand the association between the gender and the severity of COVID-19 among psychiatric patients.

Another aspect in studying the severity of infection among psychiatric patient was the effect of medications, in particular psychotropic. In the bivariate analysis the use of typical antipsychotics and anti-epileptic by the patients were associated with less COVID-19 severity. However, this association was not found in the multivariate analysis. The use of psychotropic medication and their effect on COVID-19 severity is still debated in the literature as several studies have showed that COVID-19-related severe complications were found to be more common in individuals with psychotic disorders [12, 42]. A recent retrospective study conducted by Canal-Rivero et al. among 698 patients that found that psychiatric patients using antipsychotics and adhering to therapy were less likely to catch COVID-19 and had better outcomes after infection than the general population [43]. The latter study showed that antipsychotic drugs could have a protective effect against COVID-19 lowering the
risk of contracting the virus or may have milder symptoms if they do get the virus [43]. A case–control study done by Mckeigue et al. [44] showed polypharmacy’s association with an increased risk of severe infection and the highest risk associated with antipsychotics and drugs with anticholinergic effects [44]. Another study done by Bilbul M. et al. (2020) showed that there is no strict contraindication to the use of psychotropic medication [45]. There are growing evidence that antipsychotics have anti-inflammatory characteristics that may attenuate the normal defensive function of the immune system and possibly reduce uncontrolled inflammatory responses like those found in severe COVID-19 [46]. As for the anti-epileptic drug certain medications may affect the immune system and may increase the risk of infectious diseases [47]. The consultation–liaison psychiatrist should assist the medical team for using the best psychotropic medication balanced with medical treatment to better manage psychiatric patients infected with COVID-19.

**Limitation**
The type of the study was cross sectional that could not infer causality between the associated factors. Second, the results could not be generalized to the whole psychiatric population as the patients were selected from one single site. Due to the limited sample size, comorbidities and certain signs and symptoms did not show any significant association with the severity of the COVID-19 disease. Moreover, age was not one of the most predictive factors related to severity in this study as most of the patients have the same age range around 55 years. In addition, the basic sociodemographic characteristics were not included in this study. The patients’ information and severity of the disease might be biased as the information was collected from the medical file and some of them were relied on the nurse memory that might have been affected by recall bias. A selection biased could also occur, since some patients were considered as positive COVID-19 cases without any laboratory confirmation test. The treatment collection and the patients’ characteristics were collected after the COVID-19 period which could prevent the detection of a direct effect of treatment and some important factors on the severity of the disease. Residual confounding bias is also possible, since some factors related to the severity of the COVID-19 were not assessed in this study.

**Conclusions**
The current study showed that a high rate of infection from COVID-19 was detected in a psychiatric hospital. However, the majority of psychiatric patients showed asymptomatic and mild symptoms and have lower risk of developing a severe/critical infection. Female psychiatric patients, desaturation, increase inflammation and comorbidities such as diabetes and COPD were associated with the severity of COVID-19 among psychiatric patients. Strict management of crowded floors in chronic psychiatric institutions remains the cornerstone of treatment and taking additional measures like universal masking before even having the first positive case remains the golden intervention. The identification of risk factors may be helpful for early surveillance of COVID-19 disease progression among psychiatric patients living in psychiatric institution. Clinicians should be aware of the neuropsychiatric side effects of the drugs used to treat COVID-19 patients. Some adjustments may be required to existing psychotropic or the avoidance of specific drugs when receiving medical drugs for COVID-19. More studies are needed to better understand the effect of psychotropic use and causal relation of some factors for managing mental disorders among patient with COVID-19.

**Abbreviations**
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organization; HPC: Psychiatric hospital of the Cross; ICU: Intensive care unit; USA: United State of America; PCR: Polymerase chain reaction; BMI: Body mass index; SpO2: Peripheral oxygen saturation; CRP: C-reactive protein; PPD: Purified protein derivative; COPD: Chronic obstructive pulmonary disease; NIH: National Institutes of health; PaO2/FIO2: Pressure of Arterial Oxygen to Fractional Inspired Oxygen Concentration; SPSS: Statistical Package for the Social Sciences; SD: Standard deviations; ATP: Antipsychotic; SSRI: Selective serotonin reuptake inhibitors; TCA: Tricyclic antidepressants; ORa: Adjusted Odds Ratio; SGA: Second-generation antipsychotics; FDA: Food and Drug Administration; MERS: Middle Eastern respiratory syndrome coronavirus.

**Acknowledgements**
The authors would like to thanks all the employees that helped in the data collection and the psychiatric participants who were enrolled in this study.

**Author contributions**
MZ designed the study; CH, WK, MZ drafted the manuscript; CH, MZ carried out the analysis and interpreted the results; MZ, DH, EK, AC assisted in drafting and reviewing the manuscript; EK, AC was responsible for data collection; DH supervised the course of the article. All authors read and approved the final manuscript.

**Funding**
None.

**Availability of data and materials**
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.
References

1. Druss BG. Addressing the COVID-19 pandemic in populations with serious mental illness. JAMA Psychiat. 2020. https://doi.org/10.1001/jamapsychiatry.2020.0894.

2. Shinn AK, Viron M. Perspectives on the COVID-19 pandemic and individuals with serious mental illness. J Clin Psychiatry. 2020. https://doi.org/10.4088/JCP20c013412.

3. Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization; 2020.

4. Xiang Y-T, Zhao Y-J, Liu Z-H, Li X-H, Zhao N, Cheung T, et al. The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform. Int J Biol Sci. 2020;16(10):1741.

5. Kavoor AR. Covid-19 in people with mental illness: challenges and vulnerabilities. Asian J Psychiatr. 2020. https://doi.org/10.1016/j.ajp.2020.102051.

6. Li L. Challenges and priorities in responding to COVID-19 in inpatient psychiatry. Psychiatr Serv. 2020;71:624.

7. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry. 2005;186(6):455–6.

8. Haddad C, Hallit S, Salameh P, Bou-Assi T, Zoghbi M. Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study. J Comorb. 2017;7(1):79–86.

9. Barnett A, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Head A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21(4):357–73.

10. O'Reilly K, Donohoe G, Coyle C, O'Sullivan D, Rowe A, Lesty M, et al. Prospective cohort study of the relationship between neuro-cognition, social cognition and violence in forensic patients with schizophrenia and schizoaffective disorder. BMC Psychiatry. 2015;15(1):1–17.

11. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–30.

12. Lee SW, Yang JM, Moon SY, Yoo IK, Ha EK, Kim SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025–31.

13. Barber S, Reed S, Syam N, Jones N. Severe mental illness and risks from COVID-19. Accessed 3 September 2020.

14. Ashworth M, Schofield P, Das-Munshi J. Physical health in severe mental illness. Brit J General Pract. 2017. https://doi.org/10.3399/bjgp17X692671.

15. Zoghbi M, Haddad C, Salameh P, Haddad G, Hallit S. Untreated dyslipidaemia in Lebanese patients with schizophrenia. Prim Care Companion CNS Disord. 2017. https://doi.org/10.4088/PCC.17m02099.

16. Karlberg J, Chong D, Lai W. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol. 2004;159(3):229–31.

17. Alghamdi IG, Viron M, El-Malki SS, Alghamdi MS, Alghamdi MM, El-Shemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J General Med. 2014;7:417.

18. Chen X, Chughtai AA, Dyda A, Macintyre CR. Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. Emerg Microb Infect. 2017;6(1):1–6.

19. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):200.

20. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.

21. Klang E, Soffer S, Nadkarni G, Glicksberg B, Freeman R, Horowitz C, et al. Sex differences in age and comorbidities for COVID-19 mortality in New York City. SN Comprehensive Clin Med. 2020;2(9):1319–22.

22. Vahidy FS, Pan AP, Ahnhstedt H, Muchni S, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area. PLoS ONE. 2021;16(1):e0245556.

23. Chakravarty D, Nair SS, Hammodna N, Ratnani P, Gharib Y, Wagaskar V, et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Communications Biol. 2020;3(1):1–12.

24. Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 2020;16(4):e1008520.

25. Alkhouri M, Nandurjappa A, Annie F, Bates MC, Bhatt DL. Sex differences in case fatality rate of COVID-19 insights from a multinational registry. Mayo Clin Proc. 2020. https://doi.org/10.1016/j.mayocp.2020.05.014.

26. Su W, Qiu Z, Zhou L, Hou J, Wang Y, Huang F, et al. Sex differences in clinical characteristics and risk factors for mortality among severe patients with COVID-19: a retrospective study. Aging (Albany NY). 2020;12(1):1883.

27. Rajkumar RP. COVID-19 and mental health: a review of the existing literature. Asian J Psychiatr. 2020;52:102066.

28. Ramgopal K. Coronavirus in a psychiatric hospital: It’s the worst of all worlds. NBC News https://www.nbcnews.com/health/mental-health/coronavirus-psychiatric-hospital-its-worst-all-worlds. 2020(184266).

29. Thompson JW, Jr, Mikolajewski AJ, Kissinger P, McCrossen P, Smither A, Chamarnith GD, et al. An epidemiologic study of COVID-19 patients in a state psychiatric hospital: high penetrance with early CDC guidelines. Psychiatr Serv. 2020;71(12):1285–7.

30. NI Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Bethesda: NIH; 2020.

31. Khallil A, Feghali R, Hassoun M. The Lebanese Cohort for COVID-19: A challenge for the ABO blood group system. Frontiers in Medicine 7 (2020): 585341.

32. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–68.

33. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021;49(1):82–9.

34. Zheng X, Chen J, Deng L, Fang Z, Chen G, Ye D, et al. Risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. J Med Virol. 2021;93(2):952–61.

35. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):1–15.

36. Takahashi T, Wong P, Ellington MK, Lucas C, Klein J, Israelow B, et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Communications Biol. 2020;3(1):1–12.

37. Gadi N, Wu SC, Spilimbergo PA, Moulton VR. What’s sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses. Front Immunol. 2020;11:2147.

38. Kopel J, Perissetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19: Front Public Health. 2020;8:418.

39. Shastri A, Wheat J, Agrawal S, Chaterjee N, Pradhan K, Goldfinger M, et al. Delayed clearance of SARS-CoV2 in male compared to female patients: high ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs. MedRxiv. 2020. https://doi.org/10.1101/2020.04.15.20065066.

40. Ortona E, Buonosenso D, Carfi A, Malorni W. Long Covid Kids study g. Long COVID: an estrogen-associated autoimmune disease. Cell Death Discovery. 2021. https://doi.org/10.1038/s41420-021-00464-6.

41. Fernández-de-Las-Peñas C, Martín-Guerrero JD, Pelleier-Valero OJ, Navarro-Pardo E, Gómez-Mayordomo V, Cuadrado ML, et al. Female sex is a risk factor associated with long-term post-COVID related-symptoms.
but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study. J Clin Med. 2022;11(2):413.
42. Yang H, Chen W, Hu Y, Chen Y, Zeng Y, Sun Y, et al. Pre-pandemic psychiatric disorders and risk of COVID-19: a cohort analysis in the UK Biobank. medRxiv. 2020:91:157.
43. Canal-Rivero M, Barraqán RC, García AR, Torres NG, Crespo-Facorro B, Ruiz-Vegailla M, et al. Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: a retrospective epidemiological study in a representative Spanish population. Schizophr Res. 2021;229:53.
44. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Med. 2021;19(1):1–11.
45. Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411–27.
46. Dratcu L, Boland X. Can antipsychotic use protect from COVID-19? Schizophr Res. 2021;236:1.
47. Kuroda N. Epilepsy and COVID-19: associations and important considerations. Epilepsy Behav. 2020;108:107122.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.